IgG λ type (stage IIIA) in 2000. He was first managed with vincristine, adriamycin and dexamethasone, resulting in partial response (PR), and then with cyclophosphamide and dexamethasone, resulting in complete response (CR), followed by autologous stem cell transplantation. No M-component was detected until May 2008, when a solitary plasmocytoma of the humerus appeared and was managed with thalidomide. Soon thereafter, a new, diffusely infiltrating unilateral iris lesion developed. Results. At diagnosis the patient was asymptomatic with 20/20 vision, IOP 14 mmHg, and cells in the anterior chamber. The iris was diffusely reddish with a circle of pigment epithelial cysts around the pupillary margin. The fundus was normal. He received two courses of bortezomib, a reversible proteasome inhibitor, with dexamethasone. After the 1st course, the cells and the redness of the iris disappeared. Two months after the 2nd course of bortezomib, while on lenalidomide maintenance therapy, he continued to be asymptomatic with an IOP of 14 mmHg and a normal iris. Conclusions. Bortezomib was effective in eradicating an intraocular replase of multiple myeloma in a patient who previously had received several types of conventional chemotherapy. Financial disclosure. None 1923 OTp107 TUBEROUS SCLEROSIS COMPLEX: CHARACTERIZA- TION OF OCULAR MANIFESTATIONS AND CORRELA- TIONS WITH SYSTEMIC DISEASE M.E. Turell1, E.I. Traboulsi1, A. Gupta2 , A.D. Singh1 (turellm2@ccf.org) 1. Cole Eye Institute, Cleveland Clinic Foundation, Cleveland, OH 2. Department of Pediatric Epilepsy, Cleveland Clinic Foundation, Cleveland, OH Purpose. To evaluate genotype/phenotype correlations in individuals with astrocytic hamartoma (AH) and retinal achromic patch (AP) in the setting of tuberous sclerosis complex (TSC). Methods. Participants included 132 patients from the Cleveland Clinic Foundation Tuberous Sclerosis <strong>Program</strong> (CCF-TSCP) and 907 patients from the TSC Alliance (TSC-A). Gender, age at TSC diagnosis, presence of TSC1 or TSC2 mutations, ophthalmic examination, and systemic manifestations were analyzed. Results. No difference was found in the prevalence of AH in the CCF- TSCP (36.1%) and TSC-A (34.1%) groups (p = 0.743). AH were bilateral in 43.3% and 18.1% (p = 0.009) and multiple in 40.0% and 15.3% (p = 0.008) in the CCF-TSCP and TSC-A groups respectively. In the CCF-TSCP group, AP was observed in 12.0% of patients (40.0% bilateral, 50.0% multiple). The presence of retinal features was associated with giant cell astrocytoma (37.1% vs 14.6%; p = 0.018), renal angiomyolipoma (60.0% vs 27.1%; p = 0.003), cognitive impairment (77.1% vs 43.8%; p = 0.002), and epilepsy (91.4% vs 70.8%; p = 0.022) in those with and without retinal findings respectively. In patients with retinal findings in the CCF- TSCP and TSC-A groups, mutations in TSC2 were more frequent than in TSC1, 3.3 times and 5.8 times, respectively. In those without retinal findings; the relative rates were 0.67 times and 2.3 times, respectively. Conclusions. Individuals with retinal findings are more likely to have subependymal giant cell astrocytomas, renal angiomyolipomas, cognitive impairment and epilepsy. TSC2 mutations are more frequent in patients with retinal findings than in those without. Financial disclosure. None EYELID, CONJUNTIVA & ORBIT Abstract Posters 88 Support: Research to Prevent Blindness Challenge Grant, Department of Ophthalmology, Cleveland Clinic Lerner College of Medicine 248 OTp108 INTERLEUKIN LEVELS IN AQUEOUS OF UNTREATED AND TREATED EYES WITH VITREORETINAL LYMPHO- MA Jose S. Pulido, MD, Joseph Balsanek, Brian Peters, Melissa Snyder, PhD (pulido.jose@mayo.edu) Department of Ophthalmology, Department of Laboratory Medicine and Pathology Purpose. To determine the levels of interleukin levels in aqueous samples taken at the time of intravitreal treatment in patients with vitreoretinal lymphoma Methods. Samples at the time of paracentesis were immediately placed on ice and then ELISA for interleukin levels were performed Results. 81 samples were tested. IL 10 levels had a mean of 62 with range of 0.69-624 pg/ml. IL-6 had a mean 123 pg/ml with range from 1.67-960 pg/ml. Other levels that were elevated included were MCP- 1,and IL-1ra. Conclusions. There are marked changes in interleukin levels depending upon treatment levels. IL-10 aqueous levels is a good measure of treatment response to intravitreal chemotherapeutic agents Financial disclosure. None 304 OTp109 INTRAVITREAL RITUXIMAB FOR PRIMARY INTRAOCU- LAR LYMPHOMA (PIOL) V. Kakkassery1, G. Willerding1, K. Jahnke2, A. Korfel2, U. Pleyer1, N. Stübiger1, A.M. Joussen1 (vk@charite.de) 1. Department of Ophthalmology, Charité, Berlin, Germany 2. Department of Hematology and Oncology, Campus Benjamin Franklin, Charité, Berlin, Germany Purpose. PIOL is a rare manifestation of primary central nervous system lymphoma (PCNSL). Due to its rarity, the optimal treatment of this condition has not yet been defined thus far. The chimeric monoclonal CD20 antibody rituximab offers a new intravitreal treatment option for PIOL. Here, we report on the clinical course after repeated intravitreal injections of rituximab for PIOL. Methods. Diagnosis of PIOL was confirmed by clinical investigation and vitreous biopsy in three cases. Two patients were pretreated with systemic chemotherapy for their PCNSL (ifosfamide or MTX). Ocular clinical findings (visual acuity, intraocular pressure, vitreous haze, extent of tumor) were recorded before and after rituximab therapy. Intravitreal 1mg/0,1mL rituximab injections were conducted in accordance with the German Ophthalmic Society guidelines for intravitreal injections. Data were implemented in a nationwide open registry for PIOL supported by the German Federal Ministry of Education and Research. Results. Five eyes from 3 patients received a minimum of one to a
maximum of 7 rituximab injections. After a follow up of 4 -30 months, we observed a significant reduction of vitreous haze in all eyes (measured by the Nussenblatt classification), a preserved constant visual acuity or improvement (two eyes: finger count to 20/32; 20/40 to 20/32) and tumor remission. All patients reported about a reduction of discomfort after therapy. No intraocular adverse effects have been observed. Conclusions. In our case series, we demonstrated improvement of clinical symptoms and signs in PIOL and, to some extent, visual acuity without adverse intraocular side effects after intravitreal rituximab injections. Further long-term studies are necessary to further investigate local and systemic effects and possible side effects after rituximab therapy for intraocular lymphoma. Financial disclosure. None EYELID, CONJUNTIVA & ORBIT Abstract Posters 89
- Page 1 and 2:
XV th NH City Hotel and Tower Boliv
- Page 3 and 4:
List of Congress Meetings of the In
- Page 5:
Table of Contents Welcome address K
- Page 8 and 9:
Keynote Lectures Lymphoma of the oc
- Page 10 and 11:
The venue for the Biannual Meeting
- Page 12 and 13:
Buenos Aires Downtown MAP 12 Venue
- Page 15 and 16:
MORNING 8.30-10.10 Papers (Moderato
- Page 17 and 18:
50 RES 26 USING THE GLYCOLYTIC INHI
- Page 19 and 20:
2226 RES 4 NOTCH SIGNALING PROMOTES
- Page 21 and 22:
a reduction in the number of living
- Page 23 and 24:
array further detected copy number
- Page 25 and 26:
615 RES 21 TRB2 AND SKP2 IN THE RET
- Page 27:
following treatment with 2-fluorode
- Page 30 and 31:
1909 Rb14 RESULTS OF PATIENTS WITH
- Page 32 and 33:
Posters Retinoblastoma 2006 RBp100
- Page 34 and 35:
120 RBp135 MANAGEMENT OF AN ECTOPIC
- Page 36 and 37:
After treatment, 10 patients lived
- Page 38 and 39: Methods. Six cycles of carboplatin
- Page 40 and 41: 1940 RB15 PROTON THERAPY FOR RECURR
- Page 42 and 43: 4. Fluoroscopy for cannula placemen
- Page 44 and 45: Methods. A retrospective chart revi
- Page 46 and 47: Ruth A. Kleinerman1, Chu-ling Yu1,
- Page 48 and 49: 2006 RBp100 RETINOBLASTOMA ASSESSME
- Page 50 and 51: months. Mean delay between beginnin
- Page 52 and 53: not associated with severity of RB.
- Page 54 and 55: Conclusions. During a ten-year peri
- Page 56 and 57: 30 RBp127 TREATMENT MODULATION IN R
- Page 58 and 59: (follow-up 5 years). Two years afte
- Page 61 and 62: 8.30-9.00 Poster presentations ECOp
- Page 63 and 64: Uvea (Moderators: B. Damato, M. Sag
- Page 65 and 66: Morning 8.30-9.00 Poster presentati
- Page 67 and 68: 1621 EC1 EVALUATION OF THE “HEDGE
- Page 69 and 70: Purpose. Ocular surface squamous ne
- Page 71 and 72: (cargusale@yahoo.com) Oncology Serv
- Page 73 and 74: of the tissues most commonly affect
- Page 75 and 76: 2128 RF1 RETINOBLASTOMA David H. Ab
- Page 77 and 78: Ocular Oncology Service, St Barthol
- Page 79 and 80: Arturo Irarrazaval, Pablo Cazon, Os
- Page 81 and 82: A CASE OF TEARING AND SWELLING OF T
- Page 83 and 84: 1849 ECp101 FIVE CASES OF CARCINOMA
- Page 85 and 86: patients. The isolated involvement
- Page 87: exudative fluid from the hemangioma
- Page 92 and 93: 153 UM14 PHENO-GENOTYPIC IDENTIFICA
- Page 94 and 95: 8.30-9.00 Poster presentations UMp1
- Page 96 and 97: 2253 UM1 PRELIMINARY STUDY OF VASCU
- Page 98 and 99: Purpose. To determine the presence
- Page 100 and 101: gene expression profile of melanocy
- Page 102 and 103: the rarity of UM, timely completion
- Page 104 and 105: C. Metz, T. Gkika, W. Sauerwein, N.
- Page 106 and 107: Patients in the triamcinolone group
- Page 108 and 109: 1350 Ump101 INDUCED EXPRESSION OF P
- Page 110 and 111: Purpose. To report the Results of R
- Page 112 and 113: 1547 Ump113 LONG-TERM OBSERVATIONS
- Page 114 and 115: 2038 Ump119 VALUE OF DOPPLER ANALYS
- Page 116: Methods. A total of 4070 patients w
- Page 119: First authors Naseripour, Masood No
Change language